Find what you’re looking for

December 19, 2022 | Case studies

Historic moment for Alzheimer’s treatment

Historic moment for Alzheimer’s treatment

Re:Cognition Health, specialising in the diagnosis and treatment of people with Alzheimer’s disease, is delivering the global clinical trial for Lecanemab.

A total of 1,795 volunteers in the early stages of Alzheimer’s participated in the trial, receiving fortnightly infusions of Lecanemab, a new medication developed by pharmaceutical companies Eisai and Biogen. Results demonstrated a 27% reduction in the rate of progressive cognitive decline for those on Lecanemab compared to those on a placebo, in an 18-month trial.

The trial has been hailed by international experts in Alzheimers as a “historic moment.” Re:Cognition Health’s team are optimistic the results could lead to the progression of an effective potential treatment for Alzheimer’s disease in the UK.

Dr Emer MacSweeney, the CEO and Medical Director at Re:Cognition Health and the Principal Investigator
for the trial comments:

“The results of Lecanemab are very exciting, not only as a treatment for those with early stages of Alzheimer’s, but also in forging a pathway for the development of multiple new treatments. There are many new drugs currently in clinical trials for various stages of Alzheimer’s disease and it’s certainly a very exciting time with cause for optimism.”

Read more about SRP’s innovative companies in our Annual Review 2022

Don't forget to share this post